Qyuns Therapeutics Co., Ltd. (HKG:2509)

Hong Kong · Delayed Price · Currency is HKD

16.87

+0.05 (0.30%)

Sep 30, 2026, 3:30 PM HKT

Market Cap	3.79B -49.1%
Revenue (ttm)	1.18B +219.8%
Net Income	630.46M
EPS	2.80
Shares Out	223.37M
PE Ratio	6.05
Forward PE	13.95
Dividend	n/a
Ex-Dividend Date	n/a

Volume	64,400
Open	17.17
Previous Close	16.82
Day's Range	16.69 - 17.17
52-Week Range	13.21 - 36.50
Beta	1.49
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 19, 2026

About Qyuns Therapeutics

Qyuns Therapeutics Co., Ltd., a clinical-stage biotech company, engages in the research and development of biologic therapies for autoimmune and allergic diseases in China. Its lead product candidates include QX002N, an interleukin (IL)-17A inhibitor, which completed Phase III clinical trial for the treatment of ankylosing spondylitis; and QX005N, a monoclonal antibody (mAb) blocking IL-4Ra that is in Phase III clinical trial for treating prurigo nodularis. The company also develops QX001S, which is an IL-12/L-23p40 inhibitor for psoriasis unde... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2015

Employees 353

Stock Exchange Hong Kong Stock Exchange

Ticker Symbol 2509

Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements